reports
- Wedbush Research
- Laura Chico
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conferenc...
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, announced today that the Company’s management will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with sig...
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of...
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costs NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a definitive agreement with Immedica Pharma AB (‘Immedica’), a leading global rare disease company, for the sale of its ...
- Wedbush Research
- Dylan Shindler
- Laura Chico
- Wedbush Research
BIIB BIOGEN INC.
OVID OVID THERAPEUTICS
FMCC FEDERAL HOME LOAN MORTGAGE CORPORATION
BEAM BEAM THERAPEUTICS
FNMA FEDERAL NATIONAL MORTGAGE ASSOCIATION
VERA VERA THERAPEUTICS INC
ATXS ASTRIA THERAPEUTICS INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
TLX TELIX PHARMACEUTICALS LIMITED
JBIO JADE BIOSCIENCES INC
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, ...
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company’s OV329 clinical dev...
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Fina...
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-endCash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026 NEW YORK, May 13, 2025 (GL...
- Dylan Shindler
- Laura Chico
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Health...
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET. A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Presentations s...
- Wedbush Research
TSLA TESLA INC
NVDA NVIDIA CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
DKS DICK'S SPORTING GOODS INC.
BIIB BIOGEN INC.
OVID OVID THERAPEUTICS
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
ARVN ARVINAS HOLDING
PLTR PALANTIR TECHNOLOGIES
RMBL RUMBLEON INC
HOWL WEREWOLF THERAPEUTICS INC
ATXS ASTRIA THERAPEUTICS INC
PAY PAYMENTUS HLDGS INC
DNTH DIANTHUS THERAPEUTICS INC
- Dylan Shindler
- Laura Chico
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full...
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinicTopline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerabilityOV350, Ovid’s first program in its KCC2 direct activator library, initiated a fir...
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papa...
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. “Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformat...
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care C...
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts. A live webcast of the TD Cowen presentation can be accessed through the Events & Presentations section of the co...
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare...
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed through the Events & Presentations section of the Compan...
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EBAY EBAY INC.
BPMC BLUEPRINT MEDICINES CORP.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
OVID OVID THERAPEUTICS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
YMAB Y-MABS THERAPEUTICS
SMCI SUPER MICRO COMPUTER
BEAM INC.
COGT BEAM THERAPEUTICS
IMNM COGENT BIOSCIENCES INC
VOR IMMUNOME
STX VOR BIOPHARMA
GFS SEAGATE TECHNOLOGY HLDGS PLC
GMTX GLOBALFOUNDRIES INC
ARTV GEMINI THERAPEUTICS INC
PRME ARTIVA BIOTHERAPEUTICS INC
PRIME MEDICINE INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.